首页> 外国专利> METHOD FOR EVEROLIMUS THERAPY EFFICIENCY PREDICTION FOR PATIENTS WITH METASTATIC RENAL CANCER

METHOD FOR EVEROLIMUS THERAPY EFFICIENCY PREDICTION FOR PATIENTS WITH METASTATIC RENAL CANCER

机译:预测患有转移性肾癌的患者的常温疗法疗效的方法

摘要

FIELD: medicine.;SUBSTANCE: phospho-m-TOR is determined, and HIF-1 hypoxia induced factor,α VEGF vascular endothelial growth factor and its VEGFR2 receptor are determined additionally at the pre-operative treatment stage. At HIF-1α, VEGF, VEGFR2 values in the well of 16.2 AU/mg of protein in the well; 100.5 and 82.2 pg/mg of protein, respectively, as well as phospho-m-TOR levle less than 5.5 pg/mg of protein, high efficiency of everolimus therapy is predicted. At HIF-1α, VEGF, VEGFR2 values less than 16.2 AU/mg of protein in the well, 100.5 and 82.2 pg/mg of protein, respectively, and phospho-m-TOR level more than 5.5 pg/mg of protein, low efficiency of everolimus therapy is predicted.;EFFECT: method provides high accuracy of everolimus therapy efficiency prediction, which, in turn, allows to select the appropriate therapy.;3 ex
机译:领域:医学;研究对象:在术前治疗阶段测定磷酸化m-TOR,并另外测定HIF-1缺氧诱导因子,αVEGF血管内皮生长因子及其VEGFR2受体。在HIF-1α处,孔中的VEGF,VEGFR2值为16.2 AU / mg。分别为100.5和82.2 pg / mg的蛋白质,以及低于5.5 pg / mg的磷酸-m-TOR水平,预测了依维莫司治疗的高效率。在HIF-1α处,孔中的VEGF,VEGFR2值分别小于16.2 AU / mg蛋白质,100.5和82.2 pg / mg蛋白质,并且磷酸-m-TOR水平大于5.5 pg / mg蛋白质,效率低效果:该方法提供了高精度的依维莫司治疗效率预测,进而可以选择合适的治疗方法。3

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号